Emergent Biosolutions Inc (EBS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Emergent Biosolutions Inc stock (EBS) is currently trading at $8.01. Emergent Biosolutions Inc PE ratio is 8.81. Emergent Biosolutions Inc PS ratio (Price-to-Sales) is 0.58. Analyst consensus price target for EBS is $12.00. WallStSmart rates EBS as Hold.
- EBS PE ratio analysis and historical PE chart
- EBS PS ratio (Price-to-Sales) history and trend
- EBS intrinsic value — DCF, Graham Number, EPV models
- EBS stock price prediction 2025 2026 2027 2028 2029 2030
- EBS fair value vs current price
- EBS insider transactions and insider buying
- Is EBS undervalued or overvalued?
- Emergent Biosolutions Inc financial analysis — revenue, earnings, cash flow
- EBS Piotroski F-Score and Altman Z-Score
- EBS analyst price target and Smart Rating
Emergent Biosolutions Inc
📊 No data available
Try selecting a different time range
EBS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Emergent Biosolutions Inc (EBS)
EBS trades 75% above its Graham fair value of $6.32, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Emergent Biosolutions Inc (EBS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around operating margin and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Emergent Biosolutions Inc (EBS) Key Strengths (4)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
80.98% of shares held by major funds and institutions
Supporting Valuation Data
Emergent Biosolutions Inc (EBS) Areas to Watch (6)
Losing money on operations
Revenue declining -23.60%, a shrinking business
Earnings declining -55.80%, profits shrinking
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Emergent Biosolutions Inc (EBS) Detailed Analysis Report
Overall Assessment
This company scores 55/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.38), Price/Sales (0.58), Price/Book (0.81) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, EPS Growth. Growth concerns include Revenue Growth at -23.60%, EPS Growth at -55.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.50%, Operating Margin at -15.20%, Profit Margin at 7.08%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -23.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (Operating Margin, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EBS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EBS's Price-to-Sales ratio of 0.58x trades at a deep discount to its historical average of 2.97x (15th percentile). The current valuation is 92% below its historical high of 7.31x set in Dec 2008, and 543% above its historical low of 0.09x in Jan 2024. Over the past 12 months, the PS ratio has expanded from ~0.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Emergent Biosolutions Inc (EBS) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Emergent Biosolutions Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 743M with 24% decline year-over-year. Profit margins are thin at 7.1%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 1050.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 74M in free cash flow and 78M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 24% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can Emergent Biosolutions Inc push profit margins above 15% as the business scales?
Volatility is elevated with a beta of 2.44, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Emergent Biosolutions Inc.
Bottom Line
Emergent Biosolutions Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(28 last 3 months)
| Insider | Type | Shares |
|---|---|---|
LINDAHL, RICHARD S EVP, Chief Financial Officer | Sell | -20,321 |
| Insider | Type | Shares |
|---|---|---|
PERL, JESSICA SVP, General Counsel, Corp Sec | Sell | -918 |
Data sourced from SEC Form 4 filings
Last updated: 8:26:30 AM
About Emergent Biosolutions Inc(EBS)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.